EQS-News: GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination

Positioning GeoVax as a Diversified, Made-in-America Vaccine Leader with Global Market Relevance

ATLANTA, GA - November 10, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today recognized World Immunization Day, a global observance highlighting the lifesaving power of vaccines and the urgent need to address rising concerns about vaccine confidence.

“Vaccination remains one of the most powerful tools in modern medicine, preventing millions of deaths each year,” said David A. Dodd, Chairman & CEO of GeoVax. “On World Immunization Day, we reaffirm our commitment to advancing innovative, next-generation vaccines that not only address today’s threats but also restore public trust through transparency, rigorous science, and diversified solutions.”

The Current Landscape: Trust and Innovation

• While over 90% of Americans support routine childhood immunization, surveys show declining confidence in newer vaccines and in the institutions that promote them.
• This “trust gap” underscores the need for companies like GeoVax to advance safe, transparent, and science-driven vaccine development while communicating openly with patients, providers, and policymakers.

GeoVax’s Role

• Diversified Vaccine Platforms – GeoVax’s multi-antigen vaccine candidates, including its COVID-19 vaccine GEO-CM04S1 and its GEO-MVA platform for Mpox and smallpox, are designed to provide broader, more durable immune responses.
• Addressing Vulnerable Populations – With more than 40 million immunocompromised individuals in the U.S. alone, GeoVax’s focus includes ensuring protection for patients underserved by single-antigen or mRNA-only approaches.
• Commitment to U.S. Manufacturing – GeoVax is advancing continuous cell line manufacturing to expand supply, reduce costs, and support U.S. preparedness, aligning with federal initiatives to strengthen domestic biodefense while also providing solutions to global health needs.

Looking Ahead

“Americans still believe in the power of vaccines,” added Dodd. “The challenge is ensuring that belief carries forward to the next generation of vaccines. By advancing innovation while prioritizing openness and trust, GeoVax is helping to build a future where immunization continues to save lives and protect communities worldwide.”

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:|
info@geovax.com
678-384-7220

Media Contact:
Jessica Starman
media@geovax.com 

View the original release on www.newmediawire.com